In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug

Executive Summary

Astellas Pharma badly wanted to expand its rights to FibroGen's oral anemia compounds beyond Japan. So badly, in fact, that it paid a whopping $300 million up front, agreed to up to $465 million in pre-approval milestones, and will fund half of the compounds' development in Europe and North America. Yet Astellas doesn't even get North American commercial rights in exchange: it had to settle for European and other ex-US territories.

Related Content

Can Amgen Find a New Engine?
A Look Back at 2006: The Pipeline Challenge
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
Why EPO Matters
Regional EPO Deals: Large vs. Small Molecules
Deal Statistics Quarterly, Q2 2006
Roche and Amgen Watched in Challenge over EPO
Bayer Wins Specialty CV Deal
Theravance/Astellas: Quality Deal but without the Brand Name
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts